Skip to content
Navigate to homepage - Cerba Research
Resource Library

White paper – Prioritizing Safety in CAR-T Therapy: Patient Monitoring with Cerba Research’s Testing Portfolio

In the ever-evolving landscape of healthcare, Cell and Gene Therapy (CGT) stands at the forefront of groundbreaking advancements. With the power to precisely manipulate cells and genes for therapeutic purposes, CGT offers immense promise in treating diseases at their root.

In the whitepaper “Prioritizing Safety in CAR-T Therapy: Patient Monitoring with Cerba Research’s Testing Portfolio.”  we dive into the critical realm of patient safety within CGT. Authored by industry experts, this comprehensive guide presents a novel approach to patient safety monitoring, fusing breakthroughs in flow cytometry and genomics solutions.

Key Topics Covered:

🔍 Understanding the Risks: Ensuring Patient Safety: As CGT continues to revolutionize medicine, it’s imperative to acknowledge the inherent risks associated with these therapies. From the potential for insertional oncogenesis to the emergence of replication-competent viruses, safeguarding patient safety remains paramount.

📊 Key Capabilities: Vector Copy Number (VCN) Testing, Viral Integration Site (VIS) Analysis, Replication Competent Virus Testing, Immunophenotyping and Enumeration.

⚖️ FDA Concerns: FDA’s requirements to ensure safety and adverse events

 

Reach out to our experts and discover how we can help you transform your research and advance health in the field of immune repertoire sequencing.

Resource Library

Brochure – Meeting The Challenges You Face With PBMC- All Your Global PBMC Needs Delivered

There are important questions you need to ask yourself and any potential laboratory partner before you start a study including PBMC assays as part of your protocol. When looking at the laboratory partner for your PBMC processing, approaching potential partners with the end in mind is important to ensure that you will be able to generate the data you need in the future.

Reach out to our experts and discover how we can help you advance your clinical trial

Resource Library

White paper – Lessons Learned: 10 Best Practices In Clinical Trial Operations For Virology Studies

At Cerba Research, we’ve harnessed over 35 years of unparalleled expertise in handling logistical clinical trials. Our robust logistics infrastructure is the cornerstone of swift and secure transportation, ensuring the seamless journey of delicate virological and PBMC samples from patients to laboratories.

In the whitepaper “10 Best Practices in Clinical Trial Operations for Virology Studies.”  we dive into the world of cutting-edge strategies and expert insights in clinical trial operations for virology studies from a practical point of view.

Key Topics Covered:

🔍 ROI and Clinical Trial Operations Management: Discover how optimizing operations can drive remarkable returns on investment, enhancing the success of your virology studies.

📊 Clinical Trial Operations KPIs: Delve into the metrics that truly matter, gaining insights into monitoring and measuring success effectively.

⚖️ Capacity and Demand Differences: Learn how to navigate the dynamic balance between capacity and demand to ensure your trials stay on track.

📚 Training & Knowledge Sharing in the Supply Chain: Elevate your supply chain with strategies for fostering knowledge sharing and empowering your team.

💡 Process Optimization: Streamline your operations for maximum efficiency, minimizing delays and maximizing outcomes.

🔗 Data Management in Clinical Trials: Master the art of data handling and management, a critical component of successful virology studies.

 

Reach out to our experts and discover how we can help you transform your research and advance health in the field of immune repertoire sequencing.

Resource Library

White paper – Logistics For Cell & Gene Therapy Trials: Specific Needs Demands Special Skills

The rapid increase in cell and gene therapies holds unprecedented potential. However, great innovations come with great responsibilities, especially when it comes to clinical trial logistics. Mistakes in this process can be more than just harmful – they can be costly for sponsors and, even more importantly, pose risks to patient.

The whitepaper ‘‘Logistics for Cell & Gene Therapy Trials: Specific Needs Demands Special Skills” takes you through the unique challenges of cell & gene therapy trials logistics. We shed light on potential issues and emphasize the crucial role of careful planning and execution.

📚 Key Highlights in The Whitepaper:

⚙️ Complex Logistics Unraveled: Understand the intricate logistics of Cell & Gene Therapy Trials – where precision is key.

🔬 Cerba’s Real Case Study: Join us as we tackle logistics challenges in a groundbreaking viral vector-based therapy for Spinal Muscular Atrophy (SMA). Learn from real experiences.

🌐 Experts Who Understand: Discover why specialized expertise matters for successful Cell & Gene Therapy Trials logistics.

🗺️ Managing Across Locations: Learn to efficiently handle logistics across different places while ensuring therapy integrity.

📜 Navigating Regulations: Get insights into the rules that guide these therapies and shape logistics decisions.

📊 Handling Data Right: Explore strategies for accurate, secure, and compliant data management.

 

Reach out to our experts and discover how we can help you transform your research and advance health in the field of immune repertoire sequencing.

Resource Library

White Paper – Nonnegotiable Central Laboratory Capabilities For I/O Clinical Trial Success

In immuno-oncology (I/O), meeting budget and timeline expectations in the journey from translational research to commercialization is a challenge. You need expert, integrated central laboratory and diagnostic solutions delivered by top scientists who will help you assess needs and generate early insights that optimize your protocol.

What else should you look for in a clinical laboratory partner? Along with access to a sizable patient database, impeccable performance across the globe, and I/O experience, three main testing capabilities are mandatory for success in this field: immunohistochemistry, flow cytometry, and next-generation sequencing.

Reach out to our experts & discover how we can help you transform research and advance health

Resource Library

Webinar – Turning Precision Medicine Into Action In Immuno-Oncology

The challenges in immuno-oncology (I/O) drug development require deep scientific insights, generation and analysis of complex biological data, new state-of-the art technologies and both logistical & operational support across continents. The goal of immuno-oncology drug developers is to turn precision medicine into action, bringing life-changing therapies to patients.

In this webinar originally held on October 4 our experts discuss the use of Immunohistochemistry (IHC), Next-Generation Sequencing (NGS), and Flow Cytometry (FCM) within immuno-oncology, and how they can offer the comprehensive insights required for I/O clinical trials.

Speakers

  • Jérôme Sallette, PhD, CSO Cerba Research
  • Shu Jen Chen, PhD, CSO ACT Genomics
  • Sofie Vandevyver, PhD, Head of Business Operations & Marketing Cerba Research
  • George Wei, PhD, Vice President R&D ACT Genomics
  • Renaud Burrer, PhD, Head of Histopathology Cerba Research
  • Nithianandan Selliah, PhD, Global Head Flow Cytometry Cerba Research
Resource Library

Flyer – The New Big Data Application That Is Reshaping Clinical Trials

Reach out to our experts  and discover how we can help you advance your clinical research

Resource Library

Fact Sheet – Presence And Capabilities – Running Clinical Trials In Australia Infographic

With Cerba’s network spanning five continents, team up with our experienced scientists to generate early insights and direct the course of your complex trial.

Our locations consist of cutting-edge laboratories that provide a full portfolio of specialty laboratory testing, anchored by seven centers in the Americas, Europe, Africa, and Asia-Pacific regions. With consistent, high-quality data and a road map to the patients you need, we empower you to develop personalized medicines and diagnostic solutions that will change lives worldwide.

Discover our Australia capabilities

Reach out to our experts and discover how we can help you advance your research

Resource Library

Brochure – Cerba Research’s Multi-Omics Approaches In Hematological Malignancies

Hematological malignancies originate from the uncontrolled growth of hematopoietic and lymphoid tissues. These biologically and clinically heterogeneous disorders account for 6.5% of all cancers worldwide, and for approximately 9.5% of newly diagnosed cancers every year.

Due to the high level of heterogeneity in cytogenetic, genetic, epigenetic, transcriptional, post-transcriptional, and metabolic alterations of hematological diseases, integrated multi-omics analyses are needed to improve clinical outcomes.

At Cerba Research, we aim to bring a multi-modal approach to precision medicine to disease. From discovery to clinical development, we provide world-class teams and capabilities worldwide to help you in your quest for novel treatment against hematological malignancies.

Reach out to our experts and discover how we can help you advance your research

Resource Library

Brochure – Cerba Research Biorepository Brochure

A biorepository enabled by a leading medical diagnostic and healthcare infrastructure

Since 1967, Cerba HealthCare Group has accompanied scientific and technological advances in diagnosis, prevention and precision medicine in order to better meet the expectations of health professionals and patients. This constant quest for improvement has led Cerba Research to create one of the world’ s largest and multinational commercial biorepository with the unique goal of contributing to the advancement of Science.

As a specialty and central laboratory for clinical trials covering 5 continents, our biospecimen provision is the starting point for your research to facilitate further downstream decisions inclusion: robust assay development and assay validation with quality samples.

Reach out to our experts and discover how we can help you advance your research